PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international liver congress / on track to file Pre-Market
Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the first patient has been enrolled in its MOJAVE study. MOJAVE, a randomized controlled Phase 1/2a study in the US, will .
Sequana Medical NV: Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
PRESS RELEASE Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of…
Sequana Medical Announces First Patient Enrolled in MOJAVE dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.